DK1183269T3 - Svækkede mikroorganismer til behandlingen af infektion - Google Patents

Svækkede mikroorganismer til behandlingen af infektion

Info

Publication number
DK1183269T3
DK1183269T3 DK00927538T DK00927538T DK1183269T3 DK 1183269 T3 DK1183269 T3 DK 1183269T3 DK 00927538 T DK00927538 T DK 00927538T DK 00927538 T DK00927538 T DK 00927538T DK 1183269 T3 DK1183269 T3 DK 1183269T3
Authority
DK
Denmark
Prior art keywords
infection
treatment
attenuated microorganisms
attenuated
microorganisms
Prior art date
Application number
DK00927538T
Other languages
Danish (da)
English (en)
Inventor
Gordon Dougan
Joseph David Santangelo
David William Holden
Jacqueline Elizabeth Shea
Zoe Hindle
Original Assignee
Microscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microscience Ltd filed Critical Microscience Ltd
Application granted granted Critical
Publication of DK1183269T3 publication Critical patent/DK1183269T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42—Salmonella
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DK00927538T 1999-05-10 2000-05-09 Svækkede mikroorganismer til behandlingen af infektion DK1183269T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9910812.8A GB9910812D0 (en) 1999-05-10 1999-05-10 Vaccine composition
PCT/GB2000/001749 WO2000068261A2 (en) 1999-05-10 2000-05-09 Attenuated microorganisms for the treatment of infection

Publications (1)

Publication Number Publication Date
DK1183269T3 true DK1183269T3 (da) 2007-04-02

Family

ID=10853168

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00927538T DK1183269T3 (da) 1999-05-10 2000-05-09 Svækkede mikroorganismer til behandlingen af infektion

Country Status (28)

Country Link
US (3) US6756042B1 (es)
EP (2) EP1702927B1 (es)
JP (1) JP4583607B2 (es)
KR (2) KR100680391B1 (es)
CN (1) CN1177863C (es)
AP (1) AP1470A (es)
AT (2) ATE346090T1 (es)
AU (1) AU763898B2 (es)
BR (1) BRPI0010418B8 (es)
CA (1) CA2372553C (es)
CY (1) CY1107656T1 (es)
CZ (1) CZ301926B6 (es)
DE (2) DE60043868D1 (es)
DK (1) DK1183269T3 (es)
EA (1) EA004921B1 (es)
ES (1) ES2277591T3 (es)
GB (1) GB9910812D0 (es)
HU (1) HUP0201117A3 (es)
IL (3) IL146255A0 (es)
MA (1) MA25411A1 (es)
MX (1) MXPA01011477A (es)
NO (1) NO329520B1 (es)
NZ (1) NZ539260A (es)
OA (1) OA11940A (es)
PT (1) PT1183269E (es)
TR (1) TR200702949T2 (es)
WO (1) WO2000068261A2 (es)
ZA (1) ZA200108912B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1510137A (zh) * 1994-12-09 2004-07-07 �۹���ѧ�ĸ����޹�˾ 基因的鉴定
ES2356863T3 (es) * 1998-09-04 2011-04-13 Emergent Product Development Uk Limited Mutantes de spi2 de salmonella atenuada como portadores de antígenos.
GB9910812D0 (en) * 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
GB0105924D0 (en) * 2001-03-09 2001-04-25 Microscience Ltd Promoter
US7449178B2 (en) * 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2008153772A2 (en) * 2007-05-25 2008-12-18 Emergent Product Development Gaithersburg Inc. Chlamydia vaccine comprising htra polypeptides
WO2009158240A1 (en) 2008-06-16 2009-12-30 Emergent Product Development Uk Limited Salmonella vectored vaccines against chlamydia and methods of use
EP2318515A4 (en) * 2008-08-06 2012-11-14 Emergent Product Dev Uk Ltd DIFFICULT CLOSTRIDIUM VACCINES, AND METHODS OF USE
US20120064114A1 (en) * 2008-10-21 2012-03-15 Emergent Product Development United Kingdom Use of e. coli surface antigen 3 sequences for the export of heterologous antigens
US8481052B2 (en) 2011-05-17 2013-07-09 Cj Cheiljedang Corporation Avirulent Salmonella gallinarum variants and pharmaceutical composition using the same
JP2016535766A (ja) 2013-10-11 2016-11-17 セルヴィシオ ガレゴ デ サウデ（エスイーアールジーエーエス） 弱毒化生ワクチン
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
EP3922255A1 (en) 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy
EP4124342A1 (en) 2021-07-28 2023-02-01 Prokarium Limited Cancer therapy with live attenuated bacteria
WO2023105076A1 (en) 2021-12-09 2023-06-15 Prokarium Limited Combination cancer therapy
WO2024061748A1 (en) 2022-09-21 2024-03-28 Prokarium Limited Salmonella strain with chromosomally integrated landing pad
GB202215134D0 (en) 2022-10-13 2022-11-30 Prokarium Ltd Composition

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
JP2530801B2 (ja) 1978-12-22 1996-09-04 バイオゲン インコーポレイテッド 組換えｄｎａ分子
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4837151A (en) 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US5210035A (en) 1980-05-19 1993-05-11 Board Of Trustees Of Leland Stanford Jr. University Non-reventing live vaccines
US4550081A (en) 1980-05-19 1985-10-29 The Board Of Trustees Of The Leland Stanford Jr. University Non-reverting salmonella
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US5643579A (en) * 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US5397697A (en) 1989-01-10 1995-03-14 Ciba-Geigy Corporation Identification of plant-responsive genes of bacteria
FR2664614B1 (fr) 1990-07-11 1992-10-16 Pasteur Institut Sequences nucleiques issues du genome de salmonella typhi, et leurs utilisations notamment pour le diagnostic in vitro de la presence de bacteries du genre salmonella dans les produits alimentaires.
SE9101433D0 (sv) 1991-05-13 1991-05-13 Marianne Hansson Recombinant dna sequence and its use
WO1993004202A1 (en) 1991-08-22 1993-03-04 Washington University Polynucleotide probes for salmonella
AU2778992A (en) 1991-10-07 1993-05-03 Idaho Research Foundation Inc., The Genetic construct for selection of homologous recombinants on a single selective medium
US5356797A (en) 1991-11-15 1994-10-18 Board Of Regents, The University Of Texas Membrane expression of heterologous genes
AU3130893A (en) 1991-11-15 1993-06-15 Board Of Regents, The University Of Texas System Membrane expression of heterologous genes
CA2148829A1 (en) 1992-11-06 1994-05-26 Keum Hwa Choi Avirulent live vaccine and method for immunizing animals against p. multocida pasteurellosis
WO1994026933A1 (en) 1993-05-13 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Genetic footprinting: insertional mutagenesis and genetic selection
AU3958895A (en) 1994-10-18 1996-05-06 Board Of Regents, The University Of Texas System Membrane expression of heterologous genes
CN1510137A (zh) 1994-12-09 2004-07-07 �۹���ѧ�ĸ����޹�˾ 基因的鉴定
US5700683A (en) 1995-02-17 1997-12-23 Pathogenesis Corporation Virulence-attenuating genetic deletions deleted from mycobacterium BCG
WO1997014800A1 (en) 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel saliva binding protein
WO1997018225A1 (en) 1995-11-14 1997-05-22 The General Hospital Corporation Salmonella secreted proteins and uses thereof
WO1998006428A1 (en) 1996-08-16 1998-02-19 The Uab Research Foundation Mucosal immunogens for novel vaccines
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ATE284613T1 (de) 1997-02-14 2005-01-15 Merck & Co Inc Polynukleotid-impfstoff-formulierungen
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
GB9804809D0 (en) 1998-03-06 1998-04-29 Wallis Timothy S Attenuated salmonella:materials and methods relating thereto
US6585975B1 (en) 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
ES2356863T3 (es) 1998-09-04 2011-04-13 Emergent Product Development Uk Limited Mutantes de spi2 de salmonella atenuada como portadores de antígenos.
CN1196787C (zh) 1998-11-09 2005-04-13 微科学有限公司 毒力基因和蛋白质及其用途
GB9910812D0 (en) * 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
WO2001032697A2 (en) 1999-11-05 2001-05-10 L'unite De Recherche En Biologie Moleculaire (Urbm) Des Facultes Universitaires Notre Dame De La Paix (Fundp) Virulence genes and proteins from brucella melitensis, and their use
JP3414342B2 (ja) * 1999-11-25 2003-06-09 日本電気株式会社 集積回路チップの実装構造および実装方法
EP1240332B1 (en) 1999-12-23 2008-01-23 Vmax Limited Streptococcus pyogenes virulence genes and proteins and their use
GB0011108D0 (en) 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
GB0127657D0 (en) 2001-11-19 2002-01-09 Microscience Ltd Virulence genes and proteins and their use
US7449178B2 (en) 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria

Also Published As

Publication number Publication date
WO2000068261A3 (en) 2001-02-08
NO329520B1 (no) 2010-11-01
DE60043868D1 (de) 2010-04-01
CZ20014030A3 (cs) 2002-06-12
WO2000068261A2 (en) 2000-11-16
US20040191866A1 (en) 2004-09-30
US7211264B2 (en) 2007-05-01
ZA200108912B (en) 2002-12-24
IL186993A (en) 2010-02-17
US6756042B1 (en) 2004-06-29
PT1183269E (pt) 2007-02-28
EP1702927B1 (en) 2010-02-17
AU4593200A (en) 2000-11-21
CY1107656T1 (el) 2013-04-18
ATE346090T1 (de) 2006-12-15
IL146255A0 (en) 2002-07-25
CN1360594A (zh) 2002-07-24
EA200101187A1 (ru) 2002-04-25
EP1183269B1 (en) 2006-11-22
AP1470A (en) 2005-09-26
PL354355A1 (en) 2004-01-12
BRPI0010418B8 (pt) 2021-05-25
KR20060101563A (ko) 2006-09-25
ATE457998T1 (de) 2010-03-15
AU763898B2 (en) 2003-07-31
AP2001002317A0 (en) 2001-12-31
CA2372553A1 (en) 2000-11-16
EP1183269A1 (en) 2002-03-06
NZ539260A (en) 2007-01-26
CA2372553C (en) 2011-09-27
BR0010418A (pt) 2003-07-22
DE60031974D1 (de) 2007-01-04
CZ301926B6 (cs) 2010-08-04
MXPA01011477A (es) 2002-06-04
CN1177863C (zh) 2004-12-01
EA004921B1 (ru) 2004-10-28
KR100680391B1 (ko) 2007-02-08
IL146255A (en) 2008-11-26
NO20015464D0 (no) 2001-11-08
KR100811319B1 (ko) 2008-03-07
KR20020018193A (ko) 2002-03-07
MA25411A1 (fr) 2002-04-01
JP2003509008A (ja) 2003-03-11
EP1702927A1 (en) 2006-09-20
HUP0201117A2 (en) 2002-08-28
GB9910812D0 (en) 1999-07-07
NO20015464L (no) 2001-11-08
ES2277591T3 (es) 2007-07-16
JP4583607B2 (ja) 2010-11-17
TR200702949T2 (tr) 2007-08-21
HUP0201117A3 (en) 2004-01-28
DE60031974T2 (de) 2007-03-15
OA11940A (en) 2006-04-12
US20080274139A1 (en) 2008-11-06
US7887816B2 (en) 2011-02-15
BR0010418B1 (pt) 2013-04-16

Similar Documents

Publication Publication Date Title
DK1183269T3 (da) Svækkede mikroorganismer til behandlingen af infektion
DK1459749T3 (da) (S,S)-reboxetin til behandling af inkontinens
DK2412368T3 (da) Sammensætning til behandling af ar
DK1173059T3 (da) Fremgangsmåde til forögelse af biologisk virkningsfuldhed af plantebehandlingssammensætninger
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
DE60133159D1 (de) Vakuumbehandlungsanlage
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DK0965566T3 (da) Fremgangsmåde til behandling af organisk spildevand
ATE298569T1 (de) Virus behandlung
ATE253578T1 (de) Oxazinochinolone zur behandlung von viralen infektionen
NO20013596L (no) Slambehandling
NO20022949D0 (no) Attenuerte mikroorganismer for behandling av infeksjon
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
NO20032769D0 (no) Kombinasjonsmetode for behandling av virale infeksjoner
DK1493442T3 (da) Reboxetin til behandling af perifer neuropati
ATE267598T1 (de) Virus behandlung
ATA10412001A (de) Kleinkläranlage
DK9900121Y6 (da) Minirensningsanlæg
ATA190699A (de) Abwasserreinigungsanlage
FIU990330U0 (fi) Jäteveden pienpuhdistamo
AU2003204710A1 (en) Attenuated microorganisms for the treatment of infection
FI990339A0 (fi) Jätevedenpienpuhdistamo
ATA80132000A (de) Kleinkläranlage
EE200000017A (et) Reoveepuhasti